anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A vitamin A composition comprises an ester of vitamin A uniformly dispersed throughout the reaction product of formaldehyde and partially hydrolysed casein.  The acetate, tertiary butyl acetate, pivalate, anthraquinone-b -carboxylate and hemi-succinate, and palmitate esters may be used, the palmitate being preferred.  About 5 to 25% by weight of vitamin A of antioxidants may be added, e.g. butylated hydroxy toluene, butylated hydroxy anisole, ascorbyl palmitate, a -tocopherol. About 5 to 15% of amines for example cyclohexylamine, N-ethyl-piperidine, dibutylamine may also be added. The partially hydrolysed casein may be prepared by the mild hydrolysis of casein with dilute mineral acid or proteolytic enzymes such as pepsin or trypsin and may have an a -amino nitrogen content of from less than 1% to 10% (preferably 0,5 to 7,0%).  It is conveniently used as an aqueous suspension having a solids content of about 25 to 45% (preferably about 30 to 35%) in which the vitamin A ester and antioxidants are dispersed in amounts which will give a final product having about 10,000 to 500,000 international units of vitamin A activity per gram.  Formaldehyde is added with stirring to this mixture preferably at or near room temperature, conveniently as the readily available 37% solution and stirring or mixing is continued for about 5 minutes to an hour (preferably about 15 minutes) during which time the product becomes semi-solid and some granulation may occur.  The ratio by weight of formaldehyde to partial hydrolysate of casein may vary from about 1:10 to 1:100 and is preferably 1 part to from 10 to 15 parts of hydrolysate.  The reaction mass may be granulated and dried at temperatures up to 100 DEG C. at atmospheric pressure or under vacuum to give a dry, free flowing powder which may be incorporated in animal feed supplements and pharmaceutical preparations.
Due to the remarkable success of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), allogeneic stem cell transplantation (alloSCT) is not first-line treatment for delivering durable, long-term survival. Consequently, alloSCT is reserved for patients with TKI-resistant or TKI-intolerant chronic phase CML (CP-CML) and advanced phase CML (AP-CML). Advances in transplant technology, such as high-resolution HLA typing, introduction of reduced intensity conditioning and increased alternative donor availability, coupled with improved supportive care, have significantly reduced transplant-related mortality and expanded the pool of transplant-eligible patients. Refinement of conditioning regimens, innovative use of post-transplant cellular and pharmacological therapies, and judicious post-transplant monitoring are important strategies for reducing risk of relapse. Given its potential to cure, alloSCT will invariably remain a key part of the treatment algorithm. This article reviews the data underpinning the role and outcomes of alloSCT and provides an update on current recommendations.
1. Use of treosulfan for the preparation of a pharmaceutical composition for conditioning therapy over a period of 2 to 7 days while administering of the common dose, of at least, 20 g/m<2> body surface area before allogenic transplantation of bone marrow or haematopoietic stem cells. 2. Use according to Claim 1, characterized in that the total dose amounts to 20 to 60 g/m<2> body surface area. 3. Use according 2 Claim 2, characterized in that the total dose amounts to 30 g/m<2> body surface area. 4. Use according to Claim 2, characterized in that the total dose amounts to 42 to 48 g/m<2> body surface area. 5. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place over a period of 3, 5 or 7 days. 6. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of a continuous infusion. 7. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of daily individual doses. 8. Use according to Claim 4, characterized in that the pharmaceutical composition is formulated so that it is suitable for the infusion of treosulfan over a period of 2 to 7 days, in each ease for a period of 0.5 to 24 hours per day. 9. Use according to Claims 1 to 8, characterized in that treosulfan is used with at least one further chemotherapeutic agent and/or immunosuppressive agents. 10. Use according to Claim 9, characterized in that the pharmaceutical composition is a combination preparation. 11. Use according to Claim 10, characterized in that the chemotherapeutic agent is a cytostatic agent. 12. Use according to Claim 11, characterized in that the cytostatic agent is selected from the group consisting of cyclophosphamide, thiotepa, melphalan, carboplatin or fludarabine. 13. Use according to Claims 9 to 12, characterized in that the immunosuppressive agents are immunosuppressive antibodies. 14. Use according to Claims 9 to 12 for conditioning therapy with additional whole-body irradiation of the patient. 15. Use according to Claim 12, characterized in that the cytostatic agent is cyclophosphamide, and the pharmaceutical composition is formulated so that it is suitable for the administration of 14 to 16 g treosulfan/m<2> body surface area on each of 3 consecutive days, and of 60 to 100 mg cyclophosphamide/kg body weight on each of the following 2 days.
The invention discloses pediococcus pentosaceus SBC5 and application thereof, wherein the pediococcus pentosaceus is preserved in China general microbiological culture Collection center (CGMCC No. 21595) of No. 3 of national institute of microbiological culture collection center No. 1 in North Chen West Lu No. 1 in the Korean region of Beijing in 2021, 1 month and 5 days. The pediococcus pentosaceus SBC5 has various functional characteristics, and meanwhile, the organic acid composition can be produced through fermentation, and the produced multifunctional metabolite can be further applied to preparation of biological agents.
The invention relates to a pantoprazole sodium compound. The pantoprazole sodium compound is characterized by being a pantoprazole sodium trihydrate, wherein the pantoprazole sodium trihydrate is shown as an X-ray powder diffraction figure 1 obtained by Cu-Ka radio measurement. The invention further relates to a pharmaceutical composition of the pantoprazole sodium compound. The dosage form of the pharmaceutical composition is selected from oral preparations or injection preparations, wherein the oral preparations are enteric coated tablets preferably; the injection preparations are aseptic powder needles, freeze-dried powder needles and water needles. A stability test proves that pantoprazole sodium obtained by preparation is high in stability and suitable for clinical application. The stability test proves that the pantoprazole sodium obtained by preparation is high in stability and more suitable for the clinical application, and the enteric coated tablets are high in dissolution rate.
1,129,525. Dental filling materials. MINNESOTA MINING & MFG. CO. 3 Nov., 1965 [6 Nov., 1964; 12 Oct., 1965], No. 46563/65. Heading C3P. Dental filling compositions comprise, dispersed in a colourless transparent polymerizable hardenable binder, a filler material in the form of a multitude of colourless transparent particles, the particles and binder being of different refractive indices, whereby the composition, after hardening, is translucent and capable of mimicking surrounding tooth colour, the binder which is normally liquid being hardened to a solid having a glass transition temperature above the oral temperature. The filling material may comprise glass fibres, glass wool or lithium aluminium silicate. The binder is suitably a monomeric bismethacrylate obtained by interaction of glycidyl methacrylate and bisphenol A or other bisphenol, which may include a small amount of added glycidyl methacrylate. Boron-containing complexes or dimethyl-ptoluidine may be included in the compositions to accelerate hardening. Pigment, e.g. a fluorescent pigment, is not generally used but may be included if desired in some cases. To promote adhesion with the polymerizable binder, the filler material may be pre-treated with a priming material such as a complex of chromium trichloride with a carboxylic acid, or a silane. In examples, the filling compositions also include methyl methacrylate, with or without methacrylic acid, and benzoyl peroxide catalyst.
Based on exposure-response analyses for efficacy, a relationship between drug exposure and a greater likelihood of response was observed in clinical studies. Based on exposure-response analyses for safety, a relationship between exposure and a greater likelihood of safety events, including a higher occurrence of total bilirubin elevations, was observed in clinical studies.

Cardiac Electrophysiology

Tasigna is associated with concentration-dependent QT prolongation. At a dose of Tasigna 400 mg twice daily given without food in healthy subjects, the maximum mean placebo-adjusted QTcF changes were 10.4 msec (90% CI: 2.85, 18.0). After a single dose of Tasigna 800 mg (two times the maximum approved recommended dosage) given with a high fat meal to healthy subjects, the maximum mean placebo-adjusted QTcF changes were) 18.0 msec (90% CI: 9.65, 25.8). Peak plasma concentrations in the QT study were 26% lower than or comparable with those observed in patients enrolled in the single-arm study [see Boxed Warning, Warnings and Precautions (5.2), Adverse Reactions (6.1)].
The subjects with office SBP of 130-180 mmHg with 3 antihypertensive medications of different classes including thiazide or thiazide-like diuretics and daytime average daytime SBP of ≥ 130 mmHg are enrolled in the 4-week run-in period. During run-in period, subjects will receive sevikar HCT (5/20/12.5 mg, 5/40/12.5 mg or 10/40/12.5 mg). After a 4-week run-in period, subjects who have uncontrolled average home SBP, defined as average SBP of ≥ 130 mmHg, will be randomized to either spironolactone or amiloride. 118 subjects will be randomly assigned to one of the two treatment groups. Subjects randomly assigned to one of the two treatment groups will receive 12.5 mg of spironolactone and the other group will receive 5 mg of amiloride. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone or 10 mg of amiloride. After 12 weeks of treatment, study will be end.
An emergency responder alert system. The emergency responder alert system includes a housing having a container affixed thereto, wherein the container includes a bottom, a sidewall, and an open end defining an interior volume. A power source is connected to the housing and provides power thereto. The system further includes indicia having a fastener on a rear side, wherein a front side thereof is reflective and a light source to illuminate the indicia. A speaker is disposed on the housing and is connected to a microprocessor disposed therein. The microprocessor includes a logic that activates when a control on the housing is actuated. The logic contacts emergency services to allow two-way communication via the speaker, disengages a door lock mechanism, illuminates the light source, and sends an alert to a pre-determined third-party.
Evidence suggests that components within structured days (e.g., school days) have a positive influence on children's obesogenic behaviors (i.e., diet, sleep, physical activity, sedentary behaviors) and self-regulation. In this pilot study children will be randomized to two arms: attend a structured summer camp, not attend a camp. The investigators hypothesize that children attending the summer camp will engage in more healthy obesogenic behaviors, display higher levels of self-regulation, and subsequently will experience less weight gain than children not attending the summer camp. To test this hypothesis the following specific aims will be accomplished: Aim 1 (Primary): Compare changes in BMI z-scores and fitness among children from low-income households attending a structured summer day camp and those not attending a structured summer day camp. Aim 2 (Secondary): Compare changes in obesogenic behaviors among children attending a structured summer day camp and those not attending a structured summer day camp. Aim 3 (Exploratory): Explore changes in self-regulation and the moderating effect of these changes on primary and secondary outcomes among children attending and not attending a structured summer day camp.
Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
BACKGROUND: Patients with sepsis resulting in acute lung injury (ALI) usually have increased mortality. Ferroptosis is a vital regulator in sepsis-induced ALI. Exploring the association of ferroptosis and sepsis-induced ALI is crucial for the management of sepsis-induced ALI.
METHODS: Whole blood was collected from sepsis patients. Mice were treated with cecal ligation and puncture (CLP) to model sepsis. Primary murine pulmonary microvascular endothelial cells were treated with lipopolysaccharide as a cell model. Ferroptosis was evaluated by analyzing levels of iron, malonaldehyde, glutathione, nonheme iron, ferroportin, ferritin, and GPX4. Hematoxylin and eosin and Masson's trichrome staining were applied to examine lung injury and collagen deposition. Cell apoptosis was analyzed by caspase-3 activity and TUNEL assays. Gene regulatory relationship was verified using RNA pull-down and immunoprecipitation assays.
RESULTS: CircEXOC5 was highly expressed in sepsis patients and CLP-treated mice, in which knockdown alleviated CLP-induced pulmonary inflammation and injury, and ferroptosis. CircEXOC5 recruited IGF2BP2 to degrade ATF3 mRNA. The demethylase ALKBH5 was responsible for circEXOC5 upregulation through demethylation. CircEXOC5 silencing significantly improved sepsis-induced ALI and survival rate of mice by downregulating ATF3.
CONCLUSIONS: ALKBH5-mediated upregulation of circEXOC5 exacerbates sepsis-induced ALI by facilitating ferroptosis through IGF2BP2 recruitment to degrade ATF3 mRNA.
A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises rigid membrane, push layer, drug layer, separating layer and aesthetic coating is disclosed. The rigid membrane contains semi-permeable polymer, hole-forming agent and/or plasticizer and has one or more delivery orifices on one end. The push layer comprises expanding material, permeation-promoter, binder, colorant and lubricant. The drug layer contains pharmaceutical active component, hydrophilic polymer carrier, permeation-promoter, colorant, lubricant and antistatic agent. The separating layer is between the inner surface of the rigid membrane and core comprised of drug layer and push layer and contains hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows increased release at initial stage and keeps constant release at late stage.
Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
The present invention relates to an injection for treating hemorrhoids and a preparation method thereof. The injection is prepared from crude medicines such as vermilion, sal ammoniac, alum, realgar, common salt, pearl, frankincense, myrrh, Chinese gall, etc. The injection has obvious curative effects on various kinds of internal hemorrhoids, external hemorrhoids, mixed hemorrhoids, anal fistula, anal fissure, anal damp hemorrhoids, anal angioma, etc. By the observation of clinic curative effects of 1926 curative effect observation patients, the total cure rate of the injection is higher than 90%. The injection is an injection medicine with light pain, quick curative effect, short treatment course, no complication and low relapse rate of diseases. Simultaneously, the injection has obvious curative effects on rectal cancer and mammary cancer.
Throat packs are widely used to prevent aspiration of blood and other debris, especially in orofacial surgeries and dental treatments performed under general anesthesia. Aspiration of blood and other secretions into the stomach is one of the important causes of PONV. There is not much evidence that throat packs prevent nausea and vomiting after surgery. The most critical side effects of throat pack application are sore throat, difficulty swallowing, and being forgotten before extubation.

The incidence of cavities and other dental problems is higher in special health care needs due to reasons such as inadequate oral hygiene, malocclusion, high-carbohydrate diet, and lack of awareness about dental health. In this group of patients, dental treatments are primarily performed under general anesthesia. Since side effects are more difficult to identify by the patient, the procedures, technical applications and anaesthesia methods should be those with the least potential for side effects. Evidence is needed regarding the effect of throat packing on PONV. In this study, researchers planned to investigate the effects of using throat tampons during dental treatments under general anesthesia on PONV and sore throat in participants requiring special health care.
Vertebrate animal models are essential in research; however, efforts need to be made to decrease animal suffering as much as possible. It could be useful to determine humane endpoints that could serve as surrogates for a fatal outcome. We address this issue with respect to infectious diseases. We propose a humane endpoint for studies of Sporothrix brasiliensis infection. BALB/c mice were inoculated subcutaneously in the footpad. To define a humane endpoint, we considered two groups: animals who died during the experiment, and those euthanized at the end of the experiment. The groups were compared for colony-forming units (CFU) in internal organs, clinical condition, and body weight. Thirteen (22%) animals died before the end of the experiment due to the progression of local infection to severe and disseminated sporotrichosis. Analyzing data of the groups, we propose the following future criteria for euthanasia as a humane endpoint: neurological impairment OR necrosis of the footpad OR loss of ≥ 20% body weight AND moderate to severe dehydration. In view of the current global epidemiological impact of zoonotic sporotrichosis caused by S. brasiliensis, our data could facilitate the utility of models used to study the disease, particularly therapy.
BACKGROUND: Periprosthetic joint infection (PJI) treatment has high failure rates even after 2-stage revision. Risk factors for treatment failure (TF) after staged revision for PJI are not well defined, nor is it well established how they correlate with the risks of developing an index PJI. Identifying modifiable risk factors may allow preoperative optimization, while identifying nonmodifiable risk factors can influence surgical options or advise against further surgery. We performed a systematic review and meta-analysis to better define predictors of TF in 2-stage revision for PJI.
METHODS: The PubMed, Embase, and Scopus databases were searched from their inception in December 1976 to April 15, 2023. Studies comparing patient-related variables between patients successfully treated who had 2-staged revision total hip arthroplasty (THA) and patients with persistent infections were included. Studies were screened, and 2 independent reviewers extracted data, while a third resolved discrepancies. Meta-analysis was performed on these data. There were 10,052 unique studies screened, and 21 studies met the inclusion criteria for data extraction.
RESULTS: There was good-quality evidence that obesity, liver cirrhosis, and previous failed revisions for PJI are nonmodifiable risk factors, while intravenous drug use (IVDU) and smoking are modifiable risk factors for TF after 2-stage revision for hip PJI. Reoperation between revision stages was also significantly associated with an increased risk of TF. Interestingly, other risk factors for an index PJI including male gender, American Society of Anesthesiology score, diabetes mellitus, and inflammatory arthropathy did not predict TF. Evidence on Charlson Comorbidity Index was limited.
CONCLUSIONS: Patients with a smoking history, obesity, IVDU, previous failed revision for PJI, reoperation between stages, and liver cirrhosis are more likely to experience TF after 2-stage revision THA for PJI. Modifiable risk factors include smoking and IVDU and these patients should be referred to services for cessation as early as possible before 2-stage revision THA.
Depression, which is a disease of heterogeneous etiology, is characterized by high disability and mortality rates. Gut microbiota are associated with the development of depression. To further explore any differences in the mechanisms of depression induced by gut microbiota and traditional stresses, as well as facilitate the development of microbiota-based interventions, a fecal microbiota transplantation (FMT) depression model was made. This was achieved by transplanting feces from major depressive disorder (MDD) patients into germ-free mice. Second, the mechanisms of the depression induced by gut microbiota were analyzed in comparison with those of the depression caused by different forms of stress. It turned out that mice exhibited depressive-like behavior after FMT. Then, PCR array analysis was performed on the hippocampus of the depressed mice to identify differentially expressed genes (DEGs). The KEGG analysis revealed that the pathways of depression induced by gut microbes are closely associated with immuno-inflammation. To determine the pathogenic pathways of physiological stress and psychological stress-induced depression, raw data was extracted from several databases and KEGG analysis was performed. The results from the analysis revealed that the mechanisms of depression induced by physiological and psychological stress are closely related to the regulation of neurotransmitters and energy metabolism. Interestingly, the immunoinflammatory response was distinct across different etiologies that induced depression. The findings showed that gut microbiota dysbiosis-induced depression was mainly associated with adaptive immunity, while physiological stress-induced depression was more linked to innate immunity. This study compared the pathogenesis of depression caused by gut microbiota dysbiosis, and physiological and psychological stress. We explored new intervention methods for depression and laid the foundation for precise treatment.